Uawongwattana Atcha, Posridee Kakanang, Promyo Kittipong, Thaeomor Atcharaporn, Oonsivilai Ratchadaporn
School of Food Technology, Institute of Agricultural Technology, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand.
School of Preclinical Science, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand.
Foods. 2025 Jun 9;14(12):2038. doi: 10.3390/foods14122038.
Obesity is a global health concern that elevates the risk of noncommunicable diseases (NCDs) such as type 2 diabetes, cardiovascular disease, and certain cancers. (white bean) contains α-amylase inhibitors (αAIs) that can reduce carbohydrate digestion and absorption, potentially mitigating obesity and metabolic syndrome. This study investigated the impact of extract (PVE) on obese rats. Male Wistar rats were fed either a standard diet (SD) or a cafeteria diet (CAF) for 17 weeks to induce obesity. Subsequently, rats in each dietary group were randomly assigned to receive a vehicle, low-dose PVE (200 mg/kg), high-dose PVE (300 mg/kg), or metformin (200 mg/kg) via an oral gavage for 6 weeks. The CAF group exhibited significantly greater weight gain compared to the SD group. In the CAF group, a low dose of PVE lowered postprandial glycemia during an oral glucose tolerance test (OGTT) at 60 and 120 min and decreased food and energy intake during weeks 17-20 and 18-19, respectively. In the SD group, a high dose of PVE reduced glycemia at 90 min in the OGTT, as well as body weight gain, food intake, and energy intake during week 17. However, the overall areas under the glucose curves in the OGTT were not significantly different across treatment groups ( > 0.05), and while individual time points showed changes, the overall glucose exposure (AUC) was not significantly altered. In conclusion, the αAIs present in demonstrate the potential to reduce body weight, weight gain, glycemia, total cholesterol, and triglycerides in vivo, but in the CAF group, neither PVE dose significantly altered the TC or TG. This study provides strong support for further exploring extract as a valuable functional ingredient in the food industry, particularly for developing products that aid in weight management and glycemic control.
肥胖是一个全球性的健康问题，它会增加患非传染性疾病（如2型糖尿病、心血管疾病和某些癌症）的风险。（白豆）含有α-淀粉酶抑制剂（αAIs），可以减少碳水化合物的消化和吸收，有可能减轻肥胖和代谢综合征。本研究调查了提取物（PVE）对肥胖大鼠的影响。雄性Wistar大鼠分别喂食标准饮食（SD）或自助餐饮食（CAF）17周以诱导肥胖。随后，每个饮食组的大鼠被随机分配通过口服灌胃接受载体、低剂量PVE（200mg/kg）、高剂量PVE（300mg/kg）或二甲双胍（200mg/kg），持续6周。与SD组相比，CAF组的体重增加明显更多。在CAF组中，低剂量的PVE在口服葡萄糖耐量试验（OGTT）的60分钟和120分钟时降低了餐后血糖，并分别在第17 - 20周和第18 - 19周减少了食物和能量摄入。在SD组中，高剂量的PVE在OGTT的90分钟时降低了血糖，以及在第17周时降低了体重增加、食物摄入和能量摄入。然而，OGTT中葡萄糖曲线下的总体面积在各治疗组之间没有显著差异（>0.05），虽然个别时间点显示有变化，但总体葡萄糖暴露（AUC）没有显著改变。总之，中存在的αAIs在体内显示出降低体重、体重增加、血糖、总胆固醇和甘油三酯的潜力，但在CAF组中，两种PVE剂量均未显著改变总胆固醇（TC）或甘油三酯（TG）。本研究为进一步探索提取物作为食品工业中有价值的功能成分提供了有力支持，特别是用于开发有助于体重管理和血糖控制的产品。
